Keywords: Data Processing, Liver, fat fraction, type 2 diabetes, sodium-glucose cotransporter 2 inhibitors, MRQuantif software.
Motivation: Control of hepatic steatosis is important because it is both a complication and a risk factor for type 2 diabetes.
Goal(s): To investigate the effects of sodium-glucose co-transporter-2 (SGLT2) inhibition on weight loss and liver fat content as measured by MRI-PDFF.
Approach: A chemical shift encoded multi-echo sequence was used to measure liver PDFF.
Results: A significant decrease in liver PDFF was only observed in the treated group with stronger association between weight and PDFF in this group. The novelty of this study is in the length of SGLT2-i treatment and the use of non-invasive MRI PDFF for liver fat assessment.
Impact: Hepatic steatosis is both a complication and a risk factor for type 2 diabetes. Noninvasive measurement of proton density fat fraction (PDFF) can be used to detect hepatic steatosis decrease after one year treatment with sodium-glucose co-transporter 2 inhibitors.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords